What Cannabis Companies Need To Know About Work-Related Asthma (Op-Ed)
“The cannabis industry’s unique exposures and the documented health concerns are likely to accelerate regulatory action and litigation risk.” By Erin Bass, Amy Rubenstein and Julie Vanneman, Dentons The legal cannabis industry employs more than 440,000 full-time workers across the United States (not including hemp industry employees). As legalization spreads, so do regulatory and workplace […]
What Will Marijuana Rescheduling Mean For Hemp, Which Is Already Fully Descheduled? (Op-Ed)
“Increased acceptance and understanding could drive greater consumer demand and foster more mainstream integration of hemp-derived products into appropriate regulated frameworks.” By Shawn Hauser, Vicente LLP The Drug Enforcement Administration’s (DEA) pending reclassification of marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) marks a historic and long-overdue milestone in U.S. […]
Pending Federal Hemp Legislation Could Reshape The Legal Industry By Banning Some Products (Op-Ed)
“The outcome of the debates around these provisions will determine the future of hemp-derived products in the United States, and the economic viability of the industry.” By Lauren Estevez and Joanne Caceres, Dentons US Cannabis Group As Congress returns from recess this month, the hemp industry is closely monitoring provisions that could fundamentally reshape the […]
Op-Ed: Why Cannabis Rescheduling Matters, But Still Falls Short
We’ve always stood for decriminalization and full legalization of cannabis, and that hasn’t changed. Moving cannabis from Schedule I to Schedule III isn’t enough; not even close. It’s still a half-measure that keeps the plant criminalized and controlled. Yet, we’ll take it (for now), because it offers something we can’t ignore: immediate relief for people […]